Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3602 + Penpulimab in Advanced Solid Tumors
NCT05333276Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of davelizomib in Advanced Malignant Solid Neoplasm (AMSN), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Status: unknown.
02
Drugs
davelizomib
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)
Beyond the preview
Go deeper on NCT05333276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05333276.